Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Gastric Cancer | Research

Expression characteristics and their functional role of IGFBP gene family in pan-cancer

Authors: Yingnan Liu, Shixuan Shen, Ziwei Yan, Lirong Yan, Hanxi Ding, Ang Wang, Qian Xu, Liping Sun, Yuan Yuan

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Insulin-like growth factor binding proteins (IGFBPs) are critical regulators of the biological activities of insulin-like growth factors. The IGFBP family plays diverse roles in different types of cancer, which we still lack comprehensive and pleiotropic understandings so far.

Methods

Multi-source and multi-dimensional data, extracted from The Cancer Genome Atlas (TCGA), Oncomine, Cancer Cell Line Encyclopedia (CCLE), and the Human Protein Atlas (HPA) was used for bioinformatics analysis by R language. Immunohistochemistry and qRT-PCR were performed to validate the results of the database analysis results. Bibliometrics and literature review were used for summarizing the research progress of IGFBPs in the field of tumor.

Results

The members of IGFBP gene family are differentially expressed in various cancer types. IGFBPs expression can affect prognosis of different cancers. The expression of IGFBPs expression is associated with multiple signal transduction pathways. The expression of IGFBPs is significantly correlated with tumor mutational burden, microsatellite instability, tumor stemness and tumor immune microenvironment. The qRT-PCR experiments verified the lower expression of IGFBP2 and IGFBP6 in gastric cancer and the lower expression of IGFBP6 in colorectal cancer. Immunohistochemistry validated a marked downregulation of IGFBP2 protein in gastric cancer tissues. The keywords co-occurrence analysis of IGFBP related publications in cancer showed relative research have been more concentrating on the potential of IGFBPs as tumor diagnostic and prognostic markers and developing cancer therapies.

Conclusions

These findings provide frontier trend of IGFBPs related research and new clues for identifying novel therapeutic targets for various cancers.
Appendix
Available only for authorised users
Literature
1.
Barger CJ, Branick C, Chee L, Karpf AR. Pan-cancer analyses reveal genomic features of FOXM1 overexpression in cancer. Cancers (Basel). 2019;11(2):251.PubMedCrossRef
2.
Pardini B, Cordero F, Naccarati A, Viberti C, Birolo G, Oderda M, et al. microRNA profiles in urine by next-generation sequencing can stratify bladder cancer subtypes. Oncotarget. 2018;9(29):20658–69.PubMedPubMedCentralCrossRef
3.
Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature. 2018;555(7696):371–6.PubMedPubMedCentralCrossRef
4.
5.
Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. 2014;14(5):329–41.PubMedCrossRef
6.
Haywood NJ, Slater TA, Matthews CJ, Wheatcroft SB. The insulin like growth factor and binding protein family: novel therapeutic targets in obesity & diabetes. Mol Metab. 2019;19:86–96.PubMedCrossRef
7.
Russo VC, Azar WJ, Yau SW, Sabin MA, Werther GA. IGFBP-2: The dark horse in metabolism and cancer. Cytokine Growth Factor Rev. 2015;26(3):329–46.PubMedCrossRef
8.
Price D, Muterspaugh R, Clegg B, Williams A, Stephens A, Guthrie J, et al. IGFBP-3 blocks hyaluronan-CD44 signaling, leading to increased acetylcholinesterase levels in A549 cell media and apoptosis in a p53-dependent manner. Sci Rep. 2020;10(1):5083.PubMedPubMedCentralCrossRef
9.
Hjortebjerg R. IGFBP-4 and PAPP-A in normal physiology and disease. Growth Horm IGF Res. 2018;41:7–22.PubMedCrossRef
10.
Nguyen DV, Li Calzi S, Shaw LC, Kielczewski JL, Korah HE, Grant MB. An ocular view of the IGF-IGFBP system. Growth Horm IGF Res. 2013;23(3):45–52.PubMedCrossRef
11.
Bach LA, Fu P, Yang Z. Insulin-like growth factor-binding protein-6 and cancer. Clin Sci (Lond). 2013;124(4):215–29.PubMedCrossRef
12.
Akaogi K, Okabe Y, Funahashi K, Yoshitake Y, Nishikawa K, Yasumitsu H, et al. Cell adhesion activity of a 30-kDa major secreted protein from human bladder carcinoma cells. Biochem Biophys Res Commun. 1994;198(3):1046–53.PubMedCrossRef
13.
Oh Y, Nagalla SR, Yamanaka Y, Kim HS, Wilson E, Rosenfeld RG. Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7 Recombinant human mac25 protein specifically binds IGF-I and -II. J Biol Chem. 1996;271(48):30322–5.PubMedCrossRef
14.
Smith P, Nicholson LJ, Syed N, Payne A, Hiller L, Garrone O, et al. Epigenetic inactivation implies independent functions for insulin-like growth factor binding protein (IGFBP)-related protein 1 and the related IGFBPL1 in inhibiting breast cancer phenotypes. Clin Cancer Res. 2007;13(14):4061–8.PubMedCrossRef
15.
Liu Y, Zhang M, He T, Yang W, Wang L, Zhang L, et al. Epigenetic silencing of IGFBPL1 promotes esophageal cancer growth by activating PI3K-AKT signaling. Clin Epigenetics. 2020;12(1):22.PubMedPubMedCentralCrossRef
16.
17.
18.
Wickham H. ggplot2: Elegant Graphics for Data Analysis: Springer-Verlag New York. 2016.
19.
Cohen R, Hain E, Buhard O, Guilloux A, Bardier A, Kaci R, et al. Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status. JAMA Oncol. 2019;5(4):551–5.PubMedCrossRef
20.
Passaro A, Stenzinger A, Peters S. Tumor mutational burden as a pan-cancer biomarker for immunotherapy: the limits and potential for convergence. Cancer Cell. 2020;38(5):624–5.PubMedCrossRef
21.
Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell. 2018;173(2):338-54e15.PubMedPubMedCentralCrossRef
22.
Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.PubMedCrossRef
23.
Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7.PubMedPubMedCentralCrossRef
24.
Gombos Z, Xu X, Chu CS, Zhang PJ, Acs G. Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix. Clin Cancer Res. 2005;11(23):8364–71.PubMedCrossRef
25.
Liu D, Li L, Zhang XX, Wan DY, Xi BX, Hu Z, et al. SIX1 promotes tumor lymphangiogenesis by coordinating TGFbeta signals that increase expression of VEGF-C. Can Res. 2014;74(19):5597–607.CrossRef
26.
van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–38.PubMedCrossRef
27.
Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16(1):3–34.PubMed
28.
29.
Baxter RC. Insulin-like growth factor (IGF) binding proteins: the role of serum IGFBPs in regulating IGF availability. Acta Paediatr Scand Suppl. 1991;372:107–14. discussion 15.PubMedCrossRef
30.
Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23(6):824–54.PubMedCrossRef
31.
Zheng Y, Sowers JY, Houston KD. IGFBP-1 expression promotes tamoxifen resistance in breast cancer cells via Erk pathway activation. Front Endocrinol (Lausanne). 2020;11:233.PubMedCrossRef
32.
Meng K, Cao J, Dong Y, Zhang M, Ji C, Wang X. Application of bioinformatics analysis to identify important pathways and hub genes in ovarian cancer affected by WT1. Front Bioeng Biotechnol. 2021;9:741051.PubMedPubMedCentralCrossRef
33.
Hwang DL, Huang SP, Lan WS, Lee PD. Elevated insulin, proinsulin and insulin-like growth factor-binding protein-1 in liver disease. Growth Horm IGF Res. 2003;13(6):316–21.PubMedCrossRef
34.
Xu YW, Chen H, Hong CQ, Chu LY, Yang SH, Huang LS, et al. Serum IGFBP-1 as a potential biomarker for diagnosis of early-stage upper gastrointestinal tumour. EBioMedicine. 2020;51:102566.PubMedPubMedCentralCrossRef
35.
Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, et al. Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Cancer Res. 2007;67(16):7923–8.PubMedCrossRef
36.
Cao Y, Nimptsch K, Shui IM, Platz EA, Wu K, Pollak MN, et al. Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. Int J Cancer. 2015;136(10):2418–26.PubMedCrossRef
37.
Li T, Forbes ME, Fuller GN, Li J, Yang X, Zhang W. IGFBP2: integrative hub of developmental and oncogenic signaling network. Oncogene. 2020;39(11):2243–57.PubMedPubMedCentralCrossRef
38.
Hu Q, Zhou Y, Ying K, Ruan W. IGFBP, a novel target of lung cancer? Clin Chim Acta. 2017;466:172–7.PubMedCrossRef
39.
Kaur G, Balasubramaniam SD, Lee YJ. IGFBP-2 in cervical cancer development. Exp Mol Pathol. 2020;113:104362.PubMedCrossRef
40.
Busund LT, Richardsen E, Busund R, Ukkonen T, Bjornsen T, Busch C, et al. Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol. 2005;58(4):361–6.PubMedPubMedCentralCrossRef
41.
Bai R, Cui Z, Ma Y, Wu Y, Wang N, Huang L, et al. The NF-kappaB-modulated miR-19a-3p enhances malignancy of human ovarian cancer cells through inhibition of IGFBP-3 expression. Mol Carcinog. 2019;58(12):2254–65.PubMedCrossRef
42.
Shih HJ, Chang HF, Chen CL, Torng PL. Differential expression of hypoxia-inducible factors related to the invasiveness of epithelial ovarian cancer. Sci Rep. 2021;11(1):22925.PubMedPubMedCentralCrossRef
43.
Chen X, Shao Y, Wei W, Shen H, Li Y, Chen Y, et al. Downregulation of LOX promotes castration-resistant prostate cancer progression via IGFBP3. J Cancer. 2021;12(24):7349–57.PubMedPubMedCentralCrossRef
44.
Igarashi K, Yui Y, Watanabe K, Kumai J, Nishizawa Y, Miyaura C, et al. Molecular evidence of IGFBP-3 dependent and independent VD3 action and its nonlinear response on IGFBP-3 induction in prostate cancer cells. BMC Cancer. 2020;20(1):802.PubMedPubMedCentralCrossRef
45.
Zielinska HA, Daly CS, Alghamdi A, Bahl A, Sohail M, White P, et al. Interaction between GRP78 and IGFBP-3 affects tumourigenesis and prognosis in breast cancer patients. Cancers (Basel). 2020;12(12):3821.PubMedPubMedCentralCrossRef
46.
Day TF, Kallakury BVS, Ross JS, Voronel O, Vaidya S, Sheehan CE, et al. Dual targeting of EGFR and IGF1R in the TNFAIP8 knockdown non-small cell lung cancer cells. Mol Cancer Res. 2019;17(5):1207–19.PubMedPubMedCentralCrossRef
47.
48.
Li W, Sun D, Lv Z, Wei Y, Zheng L, Zeng T, et al. Insulin-like growth factor binding protein-4 inhibits cell growth, migration and invasion, and downregulates COX-2 expression in A549 lung cancer cells. Cell Biol Int. 2017;41(4):384–91.PubMedCrossRef
49.
Wegmann BR, Schoneberger HJ, Kiefer PE, Jaques G, Brandscheid D, Havemann K. Molecular cloning of IGFBP-5 from SCLC cell lines and expression of IGFBP-4, IGFBP-5 and IGFBP-6 in lung cancer cell lines and primary tumours. Eur J Cancer. 1993;29A(11):1578–84.PubMedCrossRef
50.
Durai R, Davies M, Yang W, Yang SY, Seifalian A, Goldspink G, et al. Biology of insulin-like growth factor binding protein-4 and its role in cancer (review). Int J Oncol. 2006;28(6):1317–25.PubMed
51.
Mita K, Zhang Z, Ando Y, Toyama T, Hamaguchi M, Kobayashi S, et al. Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer. Jpn J Clin Oncol. 2007;37(8):575–82.PubMedCrossRef
52.
Zeng C, Feng X, Wang W, Lv L, Fang C, Chi L, et al. Decreased expression of insulin-like growth factor binding protein 6 is associated with gastric adenocarcinoma prognosis. Oncol Lett. 2017;13(6):4161–8.PubMedPubMedCentralCrossRef
53.
Chen Q, Qin S, Liu Y, Hong M, Qian CN, Keller ET, et al. IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker. Oncotarget. 2016;7(42):68140–50.PubMedPubMedCentralCrossRef
54.
Wang J, Luo XX, Tang YL, Xu JX, Zeng ZG. The prognostic values of insulin-like growth factor binding protein in breast cancer. Medicine (Baltimore). 2019;98(19):e15561.PubMedCrossRef
55.
Oh YS, Kim EJ, Schaffer BS, Kang YH, Binderup L, MacDonald RG, et al. Synthetic low-calcaemic vitamin D(3) analogues inhibit secretion of insulin-like growth factor II and stimulate production of insulin-like growth factor-binding protein-6 in conjunction with growth suppression of HT-29 colon cancer cells. Mol Cell Endocrinol. 2001;183(1–2):141–9.PubMedCrossRef
56.
Yi X, Zheng X, Xu H, Li J, Zhang T, Ge P, et al. IGFBP7 and the tumor immune landscape: a novel target for immunotherapy in bladder cancer. Front Immunol. 2022;13:898493.PubMedPubMedCentralCrossRef
57.
Artico LL, Laranjeira ABA, Campos LW, Correa JR, Zenatti PP, Carvalheira JBC, et al. Physiologic IGFBP7 levels prolong IGF1R activation in acute lymphoblastic leukemia. Blood Adv. 2021;5(18):3633–46.PubMedPubMedCentralCrossRef
58.
van Gils N, Verhagen H, Rutten A, Menezes RX, Tsui ML, Vermue E, et al. IGFBP7 activates retinoid acid-induced responses in acute myeloid leukemia stem and progenitor cells. Blood Adv. 2020;4(24):6368–83.PubMedPubMedCentralCrossRef
59.
Godina C, Khazaei S, Tryggvadottir H, Visse E, Nodin B, Jirstrom K, et al. Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer: a prospective cohort study. Carcinogenesis. 2021;42(11):1314–25.PubMedPubMedCentralCrossRef
60.
Zhao Q, Zhao R, Song C, Wang H, Rong J, Wang F, et al. Increased IGFBP7 expression correlates with poor prognosis and immune infiltration in gastric cancer. J Cancer. 2021;12(5):1343–55.PubMedPubMedCentralCrossRef
61.
Tang X, Mu J, Ma L, Tan Q, Wang J, Tan J, et al. IGFBP7 overexpression promotes acquired resistance to AZD9291 in non-small cell lung cancer. Biochem Biophys Res Commun. 2021;571:38–45.PubMedCrossRef
62.
Zheng R, Chen W, Xia W, Zheng J, Zhou Q. The prognostic values of the insulin-like growth factor binding protein family in ovarian cancer. Biomed Res Int. 2020;2020:7658782.PubMedPubMedCentralCrossRef
63.
Zhang GH, Zhong QY, Gou XX, Fan EX, Shuai Y, Wu MN, et al. Seven genes for the prognostic prediction in patients with glioma. Clin Transl Oncol. 2019;21(10):1327–35.PubMedCrossRef
64.
Yuan Q, Cai HQ, Zhong Y, Zhang MJ, Cheng ZJ, Hao JJ, et al. Overexpression of IGFBP2 mRNA predicts poor survival in patients with glioblastoma. Biosci Rep. 2019;39(6):BSR20190045.PubMedPubMedCentralCrossRef
65.
66.
Yang J, Hu Y, Wu J, Kong S. Effects of IGFBP-3 and GalNAc-T14 on proliferation and cell cycle of glioblastoma cells and its mechanism. J Pharm Pharmacol. 2020;72(2):218–26.PubMedCrossRef
67.
Tsai CW, Chang WS, Xu Y, Huang M, Tamboli P, Wood CG, et al. Prognostic significance of circulating insulin growth-like factor 1 and insulin growth-like factor binding protein 3 in renal cell carcinoma patients. Am J Cancer Res. 2022;12(2):852–60.PubMedPubMedCentral
68.
Gheysarzadeh A, Bakhtiari H, Ansari A, Emami Razavi A, Emami MH, Mofid MR. The insulin-like growth factor binding protein-3 and its death receptor in pancreatic ductal adenocarcinoma poor prognosis. J Cell Physiol. 2019;234(12):23537–46.PubMedCrossRef
69.
Huang Y, Chang A, Zhou W, Zhao H, Zhuo X. IGFBP3 as an indicator of lymph node metastasis and unfavorable prognosis for papillary thyroid carcinoma. Clin Exp Med. 2020;20(4):515–25.PubMedCrossRef
70.
Sakata J, Hirosue A, Yoshida R, Matsuoka Y, Kawahara K, Arita H, et al. Enhanced expression of IGFBP-3 reduces radiosensitivity and is associated with poor prognosis in oral squamous cell carcinoma. Cancers (Basel). 2020;12(2):494.PubMedCrossRef
71.
Yamamoto N, Oshima T, Yoshihara K, Aoyama T, Hayashi T, Yamada T, et al. Clinicopathological significance and impact on outcomes of the gene expression levels of IGF-1, IGF-2 and IGF-1R, IGFBP-3 in patients with colorectal cancer: overexpression of the IGFBP-3 gene is an effective predictor of outcomes in patients with colorectal cancer. Oncol Lett. 2017;13(5):3958–66.PubMedPubMedCentralCrossRef
72.
73.
Li X, Cao X, Li X, Zhang W, Feng Y. Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer. Cancer Sci. 2007;98(10):1592–6.PubMedCrossRef
74.
Wang S, Hong Q, Geng X, Chi K, Cai G, Wu D. Insulin-Like growth factor binding protein 5-A probable target of kidney renal papillary renal cell carcinoma. Biomed Res Int. 2019;2019:3210324.PubMedPubMedCentral
75.
Shkurnikov MY, Poloznikov AA, Nikulin SV, Schumacher U, Wicklein D, Sturken C, et al. Transcriptome guided drug combination suppresses proliferation of breast cancer cells. Bull Exp Biol Med. 2019;166(5):656–60.PubMedCrossRef
76.
Bei Y, Huang Q, Shen J, Shi J, Shen C, Xu P, et al. IGFBP6 regulates cell apoptosis and migration in glioma. Cell Mol Neurobiol. 2017;37(5):889–98.PubMedCrossRef
77.
Zong Z, Xin L, Tang X, Guo H. The clinical characteristics and prognostic value of IGFBP6 in glioma. Neurol Res. 2022;44(2):113–20.PubMedCrossRef
78.
Zhao C, Zhu X, Wang G, Wang W, Ju S, Wang X. Decreased expression of IGFBP6 correlates with poor survival in colorectal cancer patients. Pathol Res Pract. 2020;216(5):152909.PubMedCrossRef
79.
Yue C, Yang M, Tian Q, Mo F, Peng J, Ma Y, et al. IGFBP7 is associated to prognosis and could suppress cell survival in cholangiocarcinoma. Artif Cells Nanomed Biotechnol. 2018;46(sup2):817–25.PubMedCrossRef
80.
Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab. 2006;17(8):328–36.PubMedCrossRef
81.
Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK, et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A. 2007;104(13):5563–8.PubMedPubMedCentralCrossRef
82.
Liu QW, Li JY, Zhang XC, Liu Y, Liu QY, Xiao L, et al. Human amniotic mesenchymal stem cells inhibit hepatocellular carcinoma in tumour-bearing mice. J Cell Mol Med. 2020;24(18):10525–41.PubMedPubMedCentralCrossRef
83.
de Silva HC, Lin MZ, Phillips L, Martin JL, Baxter RC. IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer. Cell Mol Life Sci. 2019;76(10):2015–30.PubMedCrossRef
84.
Ueno K, Hirata H, Majid S, Tabatabai ZL, Hinoda Y, Dahiya R. IGFBP-4 activates the Wnt/beta-catenin signaling pathway and induces M-CAM expression in human renal cell carcinoma. Int J Cancer. 2011;129(10):2360–9.PubMedCrossRef
85.
Sajib S, Zahra FT, Lionakis MS, German NA, Mikelis CM. Mechanisms of angiogenesis in microbe-regulated inflammatory and neoplastic conditions. Angiogenesis. 2018;21(1):1–14.PubMedCrossRef
86.
Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69–84.PubMedCrossRef
87.
Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–26.PubMedCrossRef
88.
Gonzalez-Mariscal L, Miranda J, Gallego-Gutierrez H, Cano-Cortina M, Amaya E. Relationship between apical junction proteins, gene expression and cancer. Biochim Biophys Acta Biomembr. 2020;1862(9):183278.PubMedCrossRef
89.
90.
Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217–23.PubMedCrossRef
91.
Chua MW, Lin MZ, Martin JL, Baxter RC. Involvement of the insulin-like growth factor binding proteins in the cancer cell response to DNA damage. J Cell Commun Signal. 2015;9(2):167–76.PubMedPubMedCentralCrossRef
92.
Hollowood AD, Lai T, Perks CM, Newcomb PV, Alderson D, Holly JM. IGFBP-3 prolongs the p53 response and enhances apoptosis following UV irradiation. Int J Cancer. 2000;88(3):336–41.PubMedCrossRef
93.
Zhou Z, Lu H, Zhu S, Gomaa A, Chen Z, Yan J, et al. Activation of EGFR-DNA-PKcs pathway by IGFBP2 protects esophageal adenocarcinoma cells from acidic bile salts-induced DNA damage. J Exp Clin Cancer Res. 2019;38(1):13.PubMedPubMedCentralCrossRef
94.
Salem ME, Bodor JN, Puccini A, Xiu J, Goldberg RM, Grothey A, et al. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. Int J Cancer. 2020;147(10):2948–56.PubMedPubMedCentralCrossRef
95.
Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30(8):1232–43.PubMedCrossRef
96.
Innocenti F, Ou FS, Qu X, Zemla TJ, Niedzwiecki D, Tam R, et al. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. J Clin Oncol. 2019;37(14):1217–27.PubMedPubMedCentralCrossRef
97.
Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008;40(5):499–507.PubMedPubMedCentralCrossRef
98.
Kooreman NG, Kim Y, de Almeida PE, Termglinchan V, Diecke S, Shao NY, et al. Autologous iPSC-based vaccines elicit anti-tumor responses in vivo. Cell Stem Cell. 2018;22(4):501-13 e7.PubMedPubMedCentralCrossRef
99.
100.
Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482–92.PubMedCrossRef
101.
Croci DO, Zacarias Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother. 2007;56(11):1687–700.PubMedCrossRef
102.
Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–50.PubMedPubMedCentralCrossRef
103.
Fu T, Dai LJ, Wu SY, Xiao Y, Ma D, Jiang YZ, et al. Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. J Hematol Oncol. 2021;14(1):98.PubMedPubMedCentralCrossRef
104.
Sun L, Zhang X, Song Q, Liu L, Forbes E, Tian W, et al. IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway. Cancer Lett. 2021;500:132–46.PubMedCrossRef
105.
Gao S, Sun Y, Zhang X, Hu L, Liu Y, Chua CY, et al. IGFBP2 activates the NF-kappaB pathway to drive epithelial-mesenchymal transition and invasive character in pancreatic ductal adenocarcinoma. Cancer Res. 2016;76(22):6543–54.PubMedPubMedCentralCrossRef
106.
Scully T, Scott CD, Firth SM, Sedger LM, Pintar JE, Twigg SM, et al. Enhancement of mammary tumour growth by IGFBP-3 involves impaired T cell accumulation. Endocr Relat Cancer. 2018;25(2):111–22.PubMedCrossRef
107.
Longhitano L, Vicario N, Forte S, Giallongo C, Broggi G, Caltabiano R, et al. Lactate modulates microglia polarization via IGFBP6 expression and remodels tumor microenvironment in glioblastoma. Cancer Immunol Immunother. 2023;72(1):1–20.
108.
Akiel M, Guo C, Li X, Rajasekaran D, Mendoza RG, Robertson CL, et al. IGFBP7 deletion promotes hepatocellular carcinoma. Cancer Res. 2017;77(15):4014–25.PubMedPubMedCentralCrossRef
109.
Li T, Zhang C, Zhao G, Zhang X, Hao M, Hassan S, et al. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Cancer Lett. 2020;477:19–30.PubMedPubMedCentralCrossRef
110.
111.
Rutgers J. Update on pathology, staging and molecular pathol-ogy of endometrial (uterine corpus) adenocarcinoma. Future Oncol. 2015;11(23):3207–18.PubMedCrossRef
112.
113.
Lu TP, Lai LC, Tsai MH, Chen PC, Hsu CP, Lee JM, et al. Integrated analyses of copy number variations and gene expression in lung adenocarcinoma. PLoS One. 2011;6(9):e24829.PubMedPubMedCentralCrossRef
114.
Klemm F, Maas RR, Bowman RL, Kornete M, Soukup K, Nassiri S, et al. Interrogation of the Microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell. 2020;181(7):1643-60 e17.PubMedPubMedCentralCrossRef
115.
116.
Yasuoka H, Yamaguchi Y, Feghali-Bostwick CA. The pro-fibrotic factor IGFBP-5 induces lung fibroblast and mononuclear cell migration. Am J Respir Cell Mol Biol. 2009;41(2):179–88.PubMedPubMedCentralCrossRef
117.
Chesik D, De Keyser J, Wilczak N. Involvement of insulin-like growth factor binding protein-2 in activated microglia as assessed in post mortem human brain. Neurosci Lett. 2004;362(1):14–6.PubMedCrossRef
118.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.PubMedCrossRef
119.
Hanafusa T, Yumoto Y, Nouso K, Nakatsukasa H, Onishi T, Fujikawa T, et al. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett. 2002;176(2):149–58.PubMedCrossRef
120.
Ibanez de Caceres I, Cortes-Sempere M, Moratilla C, Machado-Pinilla R, Rodriguez-Fanjul V, Manguan-Garcia C, et al. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene. 2010;29(11):1681–90.PubMedCrossRef
121.
Perry AS, Loftus B, Moroose R, Lynch TH, Hollywood D, Watson RW, et al. In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer. Br J Cancer. 2007;96(10):1587–94.PubMedPubMedCentralCrossRef
122.
Wiley A, Katsaros D, Fracchioli S, Yu H. Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int J Gynecol Cancer. 2006;16(1):210–8.PubMedCrossRef
Metadata
Title
Expression characteristics and their functional role of IGFBP gene family in pan-cancer
Authors
Yingnan Liu
Shixuan Shen
Ziwei Yan
Lirong Yan
Hanxi Ding
Ang Wang
Qian Xu
Liping Sun
Yuan Yuan
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10832-3

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Construction of a radiogenomic association map of pancreatic ductal adenocarcinoma

Research

An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer

Retraction Note

Retraction Note: LncRNA NDRG1 aggravates osteosarcoma progression and regulates the PI3K/AKT pathway by sponging miR-96-5p

Research

Prognostic value of tumor necrosis based on the evaluation of frequency in invasive breast cancer

Research

Clinical outcomes in patients with solid tumors living in rural and urban areas followed via telemedicine: experience in a highly complex latin american hospital

Study protocol

A multi-centre randomized controlled trial investigating Consolidation Chemotherapy with and without oxaliplatin in distal rectal cancer and Watch & Wait

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits